CEOs trump movie stars among celeb endorsers, says survey

Share this article:
Mulling celebrity spokes-candidates for an ad campaign? Consider this: business leaders are more persuasive than athletes, movie stars or musicians, according to a Harris Interactive poll conducted on behalf of Adweek.

An online survey of 2,186 adults found that of the various strains of celebrity, 37% of consumers find famous business leaders to be most persuasive as product endorsers. Don't tell Bob Dole, but politicians came in last, with just 10% of respondents ranking them most persuasive. Fourteen percent said singers or musicians are most persuasive, 18% cited television or movie stars and 21% said athletes are tops for product plugs.

The survey found significant age differences among respondents, though. Those 55 and older were much more likely to find suits persuasive, with 46% ranking them most persuasive, while just 28% of those 18-34 ranked celebrity CEOs tops.

For drug advertisers, of course, whether or not a celeb has had personal experience with a disease is as important as anything. The persuasive power of authenticity aside, PhRMA's Guiding Principles on DTC advertising stipulate that: "Where a DTC television or print advertisement features a celebrity endorser, the endorsements should accurately reflect the opinions, findings, beliefs or experience of the endorser," and that "Companies should maintain verification of the basis of any actual or implied endorsements made by the celebrity endorser in the DTC advertisement, including whether the endorser is or has been a user of the product if applicable."

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...